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Abstract
Microbial cells embedded in a self-produced extracellular biofilm matrix cause chronic infec-
tions, e. g. by Pseudomonas aeruginosa in the lungs of cystic fibrosis patients. The antibiotic
killing of bacteria in biofilms is generally known to be reduced by 100–1000 times relative to
planktonic bacteria. This makes such infections difficult to treat. We have therefore pro-
posed that biofilms can be regarded as an independent compartment with distinct pharma-
cokinetics. To elucidate this pharmacokinetics we have measured the penetration of the
tobramycin into seaweed alginate beads which serve as a model of the extracellular poly-
saccharide matrix in P. aeruginosa biofilm. We find that, rather than a normal first order satu-
ration curve, the concentration of tobramycin in the alginate beads follows a power-law as a
function of the external concentration. Further, the tobramycin is observed to be uniformly
distributed throughout the volume of the alginate bead. The power-law appears to be a con-
sequence of binding to a multitude of different binding sites. In a diffusion model these
results are shown to produce pronounced retardation of the penetration of tobramycin into
the biofilm. This filtering of the free tobramycin concentration inside biofilm beads is
expected to aid in augmenting the survival probability of bacteria residing in the biofilm.
Introduction
Aggregates of microbial cells embedded in a self-produced extracellular matrix, otherwise
known as biofilm, lead to chronic and recurrent infections, e. g. by Pseudomonas aeruginosa
bacteria in the lungs of cystic fibrosis (CF) patients, which are difficult to treat [1]. In CF
patients, antibiotics like tobramycin are given both intravenously and topically in the lungs by
inhalation. The biofilm mode of growth provides protection of the microbial cells making them
significantly less susceptible to antimicrobial treatment compared to their planktonic counter-
parts [2]. This feature has been attributed to a number of mechanisms such as oxygen gradients
within the biofilm resulting in zones with minimal or no growth, adaptive stress responses, and
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a particular type of survivor cells called persisters [3]. Furthermore, the biofilm matrix itself may
act as a barrier retarding the diffusion of antibiotics into biofilms as seen in a recent study of
tobramycin penetration into non-mucoid P. aeruginosa biofilm [2]. Due to these physiological
properties of biofilms, distinct from the surrounding tissue during biofilm infections, Cao et al.
suggested that biofilms with their matrix form a third and independent compartment with
exclusive pharmacokinetics important for the effect of antibiotics [4]. If the pharmacokinetics of
an antibiotic within the biofilm is very particular, this effect could be substantial even in rela-
tively small biofilms and contribute to the observed reduced bacterial killing inside biofilms.
Positively charged aminoglycosides can bind to the negatively charged exopolysaccharide
alginate produced in e.g. P. aeruginosa biofilm microcolonies [4–7]. The binding of tobramy-
cin is not expected to change the equilibrium concentration of free antibiotics inside the bio-
film [8]. However, it has been speculated that the binding could produce sufficient
retardation of the exposure to allow for cells in the biofilm to adapt to the antimicrobial agent
[2, 9, 10]. With the binding-induced delayed diffusion, in combination with a relatively short
half life reducing the surrounding concentrations of tobramycin, there is a risk that the cen-
tral zones of biofilm colonies will not experience sufficient exposure of free tobramycin for
bacterial killing. In order to investigate this effect, we have measured the binding of tobramy-
cin as a function of external tobramycin concentration in the seaweed alginate biofilm matrix
model recently presented by Christophersen, Cao and coworkers [4, 11]. The findings from
these experiments are presented here.
Materials and Methods
Seaweed alginate beads were prepared by modified procedure from that previously described
by Cao et al. [4, 11]. A syringe containing 3% alginate (Protanal LF 10/60, FMC BioPolymer,
Drammen, Norway) was placed in a syringe pump and beads were generated at an alginate
flow rate of 40 ml/h. The syringe was connected to either a plastic tube or a needle to create
beads in various sizes. The tip of the plastic tube/needle was fixed exactly 8 cm above the sur-
face of a gelling bath of Tris-HCL with CaCl2, that was placed on a magnetic stirrer to prevent
the beads from adhering. The beads were kept in the gelling bath for at least one hour to stabi-
lise and harden. Afterwards the beads were washed twice with 0.9% NaCl with 12.5 mM CaCl2
as a stabiliser. The antibiotic tobramycin sulphate (ApodanNordic, Copenhagen, Denmark)
was used in the experiments.
In one series of experiments, a known total volume,Vb, of beads is added to a buffered solution
of antibiotics at concentration a0. After equilibration, the concentration of antibiotics in the solu-
tion, a, was measured using a Thermo Scientific Indiko Clinical and Specialty Chemistry System
(Thermo Fisher Scientific, Waltham, Massachusetts, USA). Average values after 8 h, 16 h, and 24
h equilibration were used. As this equipment is designed for clinical use, the lower and upper
measurement limitations for tobramycin concentrations are 0.5–10 mg/l, respectively. (Tobramy-
cin has molar mass 467.5g/mol, i. e. 1 mg/l corresponds to 2.14 μM.)Measurements beyond this
interval were diluted manually with 0.9% NaCl before analysing. Since we deviate from the manu-
facturers instructions by working in a solution without serum, the dilution and measurement pro-
cesses were checked in the range of our measurement and the accuracy of the measurement was
confirmed (S1 Fig). The total concentration inside the beads is calculated as at = (Ve/Vb)(a0 − a).
These experiments were performed with 20 beads with total volume Vb = 1 ml in each measure-
ment (radius approximately 2.3 mm). The external volume was Ve = 2 ml with concentrations of
tobramycin in the range 100–105 mg/l. Resulting total concentrations in the beads as a function of
external concentration are shown in Fig 1a. The resulting curve follows a power law with power
0.76. In Fig 1b the same data are shown normalised to the external concentration.
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Fig 1. Equilibrium concentration of Tobramycin. a) Total concentration, at, of tobramycin inside alginate
beads as a function of external tobramycin concentration. The total concentration, i. e. free + bound, follows a
power law over 5 decades covering from well below typical clinically relevant concentrations to well above.
Red and blue data points were obtained in independent experiments. b) Normalised concentration, at/a, of
tobramycin inside alginate beads as a function of external tobramycin concentration.
doi:10.1371/journal.pone.0153616.g001
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In order to verify that the tobramycin is indeed distributed homogeneously in the beads, a
series of experiments was performed using different sized beads thereby varying the surface/vol-
ume ratio by a factor 1.8. The total volume of the beads was kept constant at 1 ml while doing
so. Specifically, 17 beads of volume 1/17 ml each, 50 beads of volume 1/50ml, and 93 beads of
volume 1/93 were used. The results are shown in Fig 2. The tobramycin accumulation is seen to
be independent of the volume of the individual beads and thereby independent of the surface/
volume ratio. This is consistent with homogeneous distribution of the tobramycin in the beads.
This experiment was performed using a new batch of alginate and is therefore also an inde-
pendent control of the first experiment. The deduced power law behaviour is consistent in the
two experiments.
Analysis
The analysis is split into three subsections. In “Reaction-diffusion model” we describe a con-
ventional reaction-diffusion model of the tobramycin binding. In “Nonspecific binding” we
bring the observed power law in place and argue that it may be seen as a result of binding to dif-
ferent sites in the alginate with different affinities. Finally, in “Reaction-diffusion model with
power-law binding” we present a simplified reaction-diffusion model and the numerical solu-
tion of the model.
Reaction-diffusion model
As a first attempt to understand the influence of the biofilm on diffusion properties of tobra-
mycin, let us consider first order binding of tobramycin to a single binding site in the biofilm
Fig 2. Equilibrium concentrations of tobramycin inside alginate beads normalised to external for
three different volumes of individual beads: 1/17 ml, 1/50 ml, and 1/93 ml. The total volume of the beads
is kept constant at 1 ml by using 17, 50, and 93 beads were used in the three data sets respectively. The
surface/volume ratio is thereby varied a factor 1.8 without changing the total volume of the beads. The data is
consistent with homogeneous distribution of tobramycin in the beads.
doi:10.1371/journal.pone.0153616.g002
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matrix. The reaction-diffusion equations are then
@a
@t
¼ DDa kþamf þ kmb  l a ð1Þ
@mb
@t
¼ kþamf  kmb ð2Þ
mt ¼ mf þmb ð3Þ
where a is the molar concentration of free antibiotics, i. e. antibiotics that is not bound to the
matrix. The ﬁrst term in Eq (1) describes the isotropic diffusion of the unbound antibiotics
with diffusion constant D. The next two terms account for association of the antibiotics to free
matrix binding sites for the antibiotics with molar concentrationmf and dissociation of antibi-
otics from occupied sites with molar concentrationmb. The corresponding rate constants are
denoted k+ and k−. The last term is a hypothetical consumption/degradation of the free antibi-
otics with rate λ, e. g. representing defence from the bacteria. The free and occupied binding
sites add up to the total Eq (3). Volume exclusion and obstruction effects may be assumed
small at low concentration of polymeric substance [12–15].
In the limit of slow degradation and diffusion, quasistatic binding to the matrix can be
assumed, i. e. Eq (2) may be set equal to zero. This leads to a total concentration of antibiotics
inside the biofilm
at ¼ aþmb ¼ aþ
a
K þ a mt ð4Þ
where K = k−/k+ is the dissociation constant for the binding of antibiotics to the bioﬁlm matrix.
Saturation sets in when a* K and full saturation at a* (K +mt). While this is very different
from the observed power-law behaviour for tobramycin binding in Fig 1a, we shall proceed
applying it in the most basic model. Below, in “Nonspeciﬁc binding”, we shall see how the ﬁrst
order binding connects to the power-law behaviour.
The total antibiotics economy evolves relatively slowly and can be isolated by adding Eqs
(1) and (2)
@at
@t
¼ DDa la ð5Þ
The right-hand side reflects that only the free antibiotics participates in the diffusion (or is
consumed). By insertion of Eq (4) in Eq (5) we finally arrive at
ð 1þ K
2
ðK þ aÞ2
mt
K
Þ @a
@t
¼ DDa la ð6Þ
as a reasonably simple expression which describes the free antibiotics household.
The effect of the binding of the antibiotics to the biofilm matrix is therefore to stretch the
time needed to penetrate into the biofilm by a factor
“time scaling” ¼ 1þ K
2
ðK þ aÞ2
mt
K
ð7Þ
which remains a function of space and time via the antibiotics concentration, a. If the concen-
tration of binding sites is low there will be no effect of storing antibiotics in the matrix.
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Similarly, if the free antibiotics concentration is high, all sites will quickly be occupied, and the
effect of the storage on the timing will be reduced.
Nonspecific binding
The positively charged tobramycin generally binds well to the polysaccharide alginate matrix [5–
7]. Given the variation in the composition and size of the polysaccharide, a plausible origin for
the observed power-law behaviour would be binding to a number of different binding sites in the
alginate. Binding sites with higher dissociation constants correspond to higher off-rates, which,
in turn, occur with higher probability. As an example, a sum of contributions from bindings to
sites with dissociation constants K0 G
i and corresponding concentrationsm0F
i, i = 0, . . .,N,
at ¼ aþ
XN
i¼0
m0 F
i a
K0Gi þ a
ð8Þ
can reproduce the observed power-law behaviour for a range of choices of the parameters, K0, G,
m0, F, and N. This is just a weighted sum of contributions of the form in Eq (4). We ﬁnd that the
Fi = Gβi in the weights ensures that it adds up to a power law with power around β. For large N
and below saturation this approximation may be deduced by induction. We expected that many
terms would be needed to produce a power law over ﬁve decades, and that it would therefore be
hard to argue that this explanation were valid. However, in Fig 3 we show that a ﬁt with just two
terms in the sum sufﬁces. (N = 1, β = 0.76, K0 = 21μM,m0 = 246μM, and G = 250.) More terms
in the sum improves but slightly the ﬁt. Bearing in mind the polyanion nature of the alginate,
such a nonspeciﬁc binding model for tobramycin to the matrix appears reasonable. (The speciﬁc
ﬁt corresponds to a systematic change in number of non-speciﬁc sites, F = exp(βE/kB T), as func-
tion of the binding energy, E, where kB is the Boltzmann constant and T the absolute temperature
[16]. The exponent of β* 0.76 corresponds to 66 times more non-speciﬁc sites with 3.3 kcal/
Fig 3. Nonspecific bindingmodel. Example of a fit of the observed power law using the simple nonspecific
binding model outlined in the text. The parameters are specified in the figure.
doi:10.1371/journal.pone.0153616.g003
Diffusion Retardation by Binding of Tobramycin in an Alginate Biofilm Model
PLOS ONE | DOI:10.1371/journal.pone.0153616 April 21, 2016 6 / 11
mol weaker binding. The scaling over a factor 105 seen in Fig 1 suggests this relation to hold over
an energy range of about 10kcal/mol.)
Reaction-diffusion model with power-law binding
Let us now include the observed power-law
at ¼ a ab ð9Þ
which describes the quasi-static binding of tobramycin to the alginate matrix in place of Eq (4)
in the reaction-diffusion model. Insertion into Eq (5) leads to
ab ab1
@a
@t
¼ DDa la ð10Þ
as the equation describing the tobramycin penetration. Thus, the binding of the antibiotics to
the bioﬁlm matrix stretches the time needed to penetrate into the bioﬁlm by a factor
“time scaling” ¼ ab ab1 ð11Þ
which remains a function of space and time through the antibiotics concentration, a.
Numerical solution
Numerical solutions of the reaction-diffusion equation with power-law binding, i.e. Eq (10),
are shown in Fig 4. The numerical integration has been performed using the numerical solver
by Skeel et al. [17, 18] with adaptive discretisation set to meet the relative tolerance 10−3 and
the absolute tolerance 10−6. Free antibiotics is introduced at concentration of a = 4 mg/l at the
surface of the bead at time t = 0. This is a bit above the peak concentration in sputum of CF
patients during intravenous treatment [19, 20]. Fig 4a shows how the antibiotics diffuses into
the bead when binding is included. We observe full penetration only after t* 5R2/D. In Fig 4b
the binding is turned off and we observe full penetration already at t* 0.5R2/D, i. e. an order
of magnitude faster. Qualitatively, this is in accordance with the filtering predicted by Eq (11).
Fig 4c and 4d show how a transient introduction of antibiotics at the surface is low-pass fil-
tered when it reaches the center of the biofilm bead. When we allow for binding of the tobra-
mycin to the biofilm matrix, the concentration of free antibiotics at the center is lowered but
sustained for a longer time.
Results and Discussion
The stationary concentration of tobramycin inside alginate beads was measured as a function
of the external concentration. As can be seen in Fig 1a, it follows a power law to a good approx-
imation. In typical units used in medicine or molecular biology the observed power law reads
at ¼ 19 mM
a
1 mM
 0:76
ð12Þ
at ¼ 16mg=l
a
1mg=l
 0:76
ð13Þ
The accumulation of tobramycin was confirmed to be consistent with homogeneous distri-
bution in the beads. This was done in a series of experiments where the surface-to-volume
ratio was varied a factor two without changing at/a as shown in Fig 2. The power law was
found to be consistent with nonspecific binding to sites in the polyanion biofilm matrix.
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In Fig 1b we observe that the ratio, at/a, of concentrations of tobramycin inside the beads to
the external concentration keeps rising as the tobramycin concentration goes down. The effec-
tive diffusion constant, D/(αβaβ−1), is proportional to (at/a)
−1. Therefore the diffusion becomes
slower at low concentrations of tobramycin where the non-specific binding of antibiotics mole-
cules is relatively stronger. This explains why, in the work of Cao et al. [4], it was observed that
it is very hard to “wash out” the tobramycin from the beads.
The power-law scaling of the binding also implies that, when tobramycin is introduced at
the surface of the bead, a “front” builds up as the low number of antibiotics molecules ahead of
Fig 4. Tobramycin diffusion. Numerical solution of the reaction-diffusion equation with power-law binding to the biofilm matrix in a spherical bead with
radius R and diffusion constant D for the free tobramycin. The free tobramycin is displayed as a function of radius and time. Time is expressed in units of R2/
D. a) With binding. The external concentration of tobramycin is kept at a = 4 mg/l from time t = 0. The maximum time shown is t = 5R2/D. b) Without binding.
The maximum time shown is t = 0.5R2/D. c) With binding, external concentration is kept at a = 4 mg/l from time t = 0 to t = R2/D. d) Without binding, external
concentration is kept at a = 4 mg/l from time t = 0 to t = R2/D.
doi:10.1371/journal.pone.0153616.g004
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the front binds more and thereby moves slower than the bulk of the diffusing molecules. The
front is seen quite clearly in Fig 4a and 4c.
At typical clinical doses,*5 mg/kg, the peak serum concentration is of order*20 mg/kg
[19], and the peak concentration in sputum is*3.6 mg/l during intravenous treatment [20]. At
this concentration, the time stretching is about a factor 9 growing to a factor 12 at a* 1 mg/l.
The diffusion constant for tobramycin in water at 37°C is aroundD = 1.4 mm2/h [7]. For a
medium sized biofilm bead of radius R = 100 μm [9, 21–25] the characteristic time, R2/D, is 0.4
min which, by the time scaling, becomes about 4 min. In the human body, the elimination half
life for an aminoglycoside (gentamicin) is of order 2.0 h [26], i. e. much slower than the diffusion
time. In order to aid in protecting the bacteria against tobramycin treatment, the tobramycin
buffering would therefore have to act in concert with other mechanisms, e. g. an active defence
mechanism of the bacteria.
However, for a very large sized microcolony, say R* 1 mm, the filtering is, but marginally,
able to keep the concentration of free tobramycin at the center of the biofilm below the MIC of
2 mg/l during treatment. Microcolonies this large have only been reported on foreign bodies
[24] and not in sputum of CF patients.
In the present study, we have kept the composition of the biofilm matrix constant with a
concentration of 3%. Clinical extracts display alginate concentrations ranging from 0.4% to
10% with a median around 3.5% [27, 28]. We expect that the prefactor, α, will be proportional
to the density of the biofilm matrix. Thus the low-pass filtering will be even more pronounced
in the more dense biofilm aggregates and will likely play an important role in the protection of
the bacteria.
Conclusions
The penetration and binding of tobramycin into seaweed alginate beads have been measured.
The tobramycin is found to be homogeneously distributed in the beads. Surprisingly, we find
that the total concentration of tobramycin inside the biofilm matrix displays a power-law
dependence on the external concentration over five decades. Non-specific binding of tobramy-
cin to the polyanion polysaccharide biofilm matrix was presented as a plausible explanation for
the observed power-law.
The observed power-law behaviour was used in a reaction-diffusion model to demonstrate
that the tobramycin storage capacity is sufficient to produce pronounced low-pass filtering of
the free tobramycin concentration inside the bead. These calculations also showed that in very
large colonies the delay caused by the binding is sufficient to keep the tobramycin below the
MIC level at the center.
In clinical extracts, biofilm aggregates display algenate densities ranging from 0.4% to 10%.
In the more dense microcolonies of this distribution, we expect the retardation of the diffusion
to contribute significantly to the protection of bacteria residing in the biofilm.
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S1 Fig. Check of calibration. The concentration of tobramycin in the buffer, a, measured as
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